Table 1.

Patient and treatment characteristics

		Patients
No. of patients evaluable/completing treatment		74/76
Gender	Male	38
	Female	36
Age at treatment (years)	Median	61 (range 40-80)
ECOG performance status	Median	0 (range 0-2)
0		50
1		22
2		2
Status of extrahepatic disease
NED (no evidence of disease)		39 (53%)
SD/PD (stable/progressive)		35 (47%)
Previous treatment per irradiated lesion
No previous treatment		23 (25.3%)
Chemotherapy		44 (48.4%)
Endocrine therapy		3 (3.3%)
Local therapy (surgery, radiofrequency ablation)		4 (4.4%)
Combination of local and systemic treatment		17 (18.6%)
Follow up (months)	Median	15 (range 3-103)
Primary tumor	Colorectal	37
	Breast	12
	Esophageal	5
	Stomach/Pancreas/Bile duct	7
	Lung	2
	Other	11
		Lesions
Total No. of lesions evaluated/treated		91/95
Lesions per patient	Mean	1.23 (range 1-4)
Total PTV dose at 60-95% IDL	Median	35 (range 18-37.5)
(Gy)
Single PTV dose at 60-95% IDL	Median	7 (range 5-12.5)
(Gy)
Fractions	Median	5 (range 2-5)
Minimum BED to GTV	Median	91.2 Gy (18.7-183.5Gy)
Gross tumor volume GTV (cc)	Median	45 (range 1.3-699)
<100		65
100-200		12
>200		12
Planning target volume PTV (cc)	Median	123 (range 10.6-1074)